Novavax Inc (NVAX) SEC Filings — 2024
36 SEC filings for Novavax Inc (NVAX) in 2024.
Filings
- Novavax Completes Asset Acquisition/Disposition — 8-K · Dec 30, 2024
- Novavax Signs Material Definitive Agreement — 8-K · Dec 18, 2024
- Novavax Enters Material Definitive Agreement — 8-K · Dec 4, 2024
- Novavax Files 8-K Report — 8-K · Nov 20, 2024
- Novavax Files 8-K with Financials and Other Events — 8-K · Nov 12, 2024
- Novavax Q3 Revenue Flat, Net Loss Widens Amid Equity Offering — 10-Q · Nov 12, 2024
- Novavax Inc SC 13G/A Filing — SC 13G/A · Nov 12, 2024
- Novavax Enters and Terminates Material Agreements — 8-K · Nov 5, 2024
- Novavax Inc SC 13G/A Filing — SC 13G/A · Nov 4, 2024
- Novavax Files 8-K Report — 8-K · Oct 16, 2024
- Novavax Partners with Sanofi on Flu/COVID-19 Vaccine — 8-K · Oct 3, 2024
- Novavax Q2 Revenue Drops, Net Loss Narrows — 10-Q · Aug 8, 2024
- Novavax Inc SC 13G/A Filing — SC 13G/A · Jul 10, 2024
- Novavax Inc SC 13G/A Filing — SC 13G/A · Jun 20, 2024
- Novavax Appoints New CEO, Dr. John C. Jacobs — 8-K · Jun 14, 2024
- Novavax Files 8-K Report — 8-K · Jun 6, 2024
- Novavax Amends 2024 Proxy Statement — DEFA14A · Jun 5, 2024
- Novavax Appoints Dr. John C. Jacobs as New CEO — 8-K · May 23, 2024
- Shah Capital Management Amends Novavax Stake Filing — SC 13D/A · May 20, 2024
- Novavax Acquires Takeda's Vaccine Business — 8-K · May 13, 2024
- Novavax Files 8-K: Financials and Operations Update — 8-K · May 10, 2024
- Novavax Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024
- Shah Capital Management Amends Novavax Stake Filing — SC 13D/A · May 7, 2024
- Novavax Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Apr 29, 2024
- Novavax Files 8-K Report — 8-K · Apr 26, 2024
- Shah Capital Amends Novavax Stake Filing — SC 13D/A · Apr 15, 2024
- Novavax Secures $300M Credit Facility — 8-K · Mar 26, 2024
- Novavax Inc SC 13G/A Filing — SC 13G/A · Mar 7, 2024
- Novavax Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 28, 2024
- Novavax Reports Entry and Termination of Material Agreements — 8-K · Feb 22, 2024
- Vanguard Trims Novavax Stake to 0.19% as of Dec 29, 2023 — SC 13G/A · Feb 13, 2024
- Morgan Stanley Discloses Passive Stake in Novavax (NVAX) — SC 13G · Feb 9, 2024
- Novavax Reports Costs Tied to Exit/Disposal Activities — 8-K · Jan 31, 2024
- BlackRock Amends Novavax Stake, Signals Passive Investment — SC 13G/A · Jan 26, 2024
- State Street Amends Novavax Stake, Signals Institutional Confidence — SC 13G/A · Jan 25, 2024
- Novavax 8-K: Financial Condition & Operations Update — 8-K · Jan 8, 2024